Comparison of the safety of docetaxel combined with carboplatin regimen and epirubicin combined with cyclophosphamide sequential docetaxel regimen in phase Ⅲ clinical study of negative breast cancer
10.3969/j.issn.1005-1678.2017.10.072
- VernacularTitle:多西他赛联合卡铂方案与表柔比星联合环磷酰胺序贯多西他赛方案辅助治疗三阴性乳腺癌Ⅲ期临床研究的安全性比较
- Author:
ming De LV
1
;
juan Bao FU
;
ming Chao WANG
;
Sheng LV
;
xia Cai ZU
Author Information
1. 浙江金华广福肿瘤医院 普外科
- Keywords:
docetaxel;
carboplatin;
epirubicin;
three negative breast cancer;
safety
- From:
Chinese Journal of Biochemical Pharmaceutics
2017;37(10):177-178
- CountryChina
- Language:Chinese
-
Abstract:
Objective To compare the clinical efficacy and safety of docetaxel combined with carboplatin (TP) and epirubicin combined with cyclophosphamide sequential docetaxel (EC-T) adjuvant in the treatment of three negative breast cancer in phase III . Methods 62 cases of three negative breast cancer patients in phase III from May 2012 to October 2016 were selected and randomly divided into the control group and the experimental group, with 31 patients in each group. The control group was treated with epirubicin combined with cyclophosphamide and sequential docetaxel, and the experimental group was treated with docetaxel and carboplatin. The clinical indicators were compared and analyzed. Results There was no significant difference in the recent remission rate (77.42%) between the experimental group and the control group (74.19%). Two groups of patients with adverse reactions were restored within one month. There were 10 cases of WBC decrease in the experimental group, with the incidence rate of 32.25%. There were 18 cases of WBC decrease in the control group, the incidence rate was 58.06%, the difference was statistically significant (P<0.05). Conclusion Docetaxel combined with carboplatin and epirubicin adjuvant combined with cyclophosphamide than star sequential docetaxel in the treatment of three patients with negative breast cancer stage III were tolerated, TP occurred leukopenia and alopecia with low probability.
